Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid

被引：9

作者：

Said, Jordan T. ^{[1
,2
]}

Talia, Jordan ^{[1
]}

Wei, Erin ^{[1
,2
]}

Mostaghimi, Arash ^{[1
,2
]}

Semenov, Yevgeniy ^{[2
,3
]}

Giobbie- Hurder, Anita ^{[4
]}

Chen, Steven T. ^{[2
,3
,6
]}

LeBoeuf, Nicole R. ^{[1
,2
,5
,7
]}

机构：

[1] Brigham & Womens Hosp, Dept Dermatol, Boston, MA USA

[2] Harvard Med Sch, Boston, MA USA

[3] Massachusetts Gen eral Hosp, Dept Dermatol, Boston, MA USA

[4] Dana Farber Canc Inst, Dept Biostat, Boston, MA USA

[5] Dana Farber Canc Inst, Ctr Cutaneous Oncol, Boston, MA USA

[6] Massachusetts Gen Hosp, Dept Dermatol, 50 Staniford St Suite 200, Boston, MA 02215 USA

[7] Brigham & Womens Hosp, Dept Dermatol, 375 Longwood Ave, Boston, MA 02115 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 88卷 / 03期

关键词：

biologics; bullous pemphigoid; cancer; checkpoint inhibition; CTLA-4; dupilumab; immune checkpoint inhibition; immune-related adverse events; immunobiologics; inverse weighted probability regression; omalizumab; oncology; overall survival; PD-1; progression-free survival; rituximab; skin toxicity; time to progression;

D O I：

10.1016/j.jaad.2022.06.1186

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

[No abstract available]

引用

页码：670 / 671

页数：2

共 5 条

[1] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[2] Reply to: "Comment on 'Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes'" [J].

Nelson, Caroline A. ;

Singer, Sean ;

Chen, Tianqi ;

Puleo, Ashleigh Eberly ;

Lian, Christine G. ;

Wei, Erin X. ;

Giobbie-Hurder, Anita ;

Mostaghimi, Arash ;

LeBoeuf, Nicole R. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (06) :E245-E248

[3] Bullous pemphigoid after anti-programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes [J].

Nelson, Caroline A. ;

Singer, Sean ;

Chen, Tianqi ;

Puleo, Ashleigh Eberly ;

Lian, Christine G. ;

Wei, Erin X. ;

Giobbie-Hurder, Anita ;

Mostaghimi, Arash ;

LeBoeuf, Nicole R. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (06) :1400-1402

[4] Treatment Outcomes of Immune-Related Cutaneous Adverse Events [J].

Phillips, Gregory S. ;

Wu, Jennifer ;

Hellmann, Matthew D. ;

Postow, Michael A. ;

Rizvi, Naiyer A. ;

Freites-Martinez, Azael ;

Chan, Donald ;

Dusza, Stephen ;

Motzer, Robert J. ;

Rosenberg, Jonathan E. ;

Callahan, Margaret K. ;

Chapman, Paul B. ;

Geskin, Larisa ;

Lopez, Adriana T. ;

Reed, Vanessa A. ;

Fabbrocini, Gabriella ;

Annunziata, Maria Carmela ;

Kukoyi, Oluwaseun ;

Pabani, Aliyah ;

Yang, Chih-Hsun ;

Chung, Wen-Hung ;

Markova, Alina ;

Lacouture, Mario E. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) :2746-+

[5] Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy [J].

Siegel, Jacob ;

Totonchy, Mariam ;

Damsky, William ;

Berk-Krauss, Juliana ;

Castiglione, Frank, Jr. ;

Sznol, Mario ;

Petrylak, Daniel P. ;

Fischbach, Neal ;

Goldberg, Sarah B. ;

Decker, Roy H. ;

Stamatouli, Angeliki M. ;

Hafez, Navid ;

Glusac, Earl J. ;

Tomayko, Mary M. ;

Leventhal, Jonathan S. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (06) :1081-1088

← 1 →